Start the conversation
High-margin specialty drugs offer the best profit opportunity in the pharmaceutical market. And within that sector, Hepatitis C drugs will see a 200% increase in spending over the next two years. The best play in that field is Gilead Sciences Inc. (Nasdaq: GILD), which sells two highly effective and high-profit drugs for the treatment of Hepatitis C.
GILD stock is already up 11% in 2015 and 25.3% in the last 12 months.
In the current quarter, GILD is expected to grow earnings by 52.7% from last year. Revenue is expected to jump 35% in the quarter. The company also boasts an operating margin of 61.8%.